help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Healy, D. L.
Right arrow Articles by Fraser, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Healy, D. L.
Right arrow Articles by Fraser, H. M.

Journal of Clinical Endocrinology & Metabolism, Vol 63, 619-625, Copyright © 1986 by Endocrine Society

ARTICLES

Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase

DL Healy, SR Lawson, M Abbott, DT Baird and HM Fraser

Intermittent sc injection of a LHRH agonist reduced uterine fibroid size in 5 women. Commencement of the LHRH agonist buserelin on day 21 of the menstrual cycle induced a marked increase in plasma LH and FSH concentrations, followed by rises in estradiol (E2) and progesterone. LH and FSH levels fell to within the normal range by 120 h after beginning buserelin, despite continuing administration of the agonist. After menstruation, marked sustained suppression of cyclical gonadotropin and steroid concentrations occurred: mean values of FSH, LH, and E2 were 4.9 +/- 0.5 (+/- SE) mIU/ml, 5.9 +/- 0.6 mIU/ml, and 47.9 +/- 10.8 pg/ml, respectively, during the 20 weeks of buserelin treatment. During treatment, E2 concentrations remained below 50 pg/ml in 98 of 116 weekly observations. Uterine fibroids shrank after 8 or 10 weeks of buserelin administration, as assessed by ultrasound or gynecological examination. Compared to their initial volume, mean uterine fibroid volume after 20 weeks of buserelin infusion decreased from 220 +/- 51 to 98 +/- 26 cm3, which was 39.4 +/- 6.9% of the pretreatment volume. We conclude that sc administration of a LHRH agonist beginning in the luteal phase markedly reduced the size of uterine leiomyomata, suppressed, but did not abolish, pituitary and ovarian function, and warrants further evaluation as an option or adjunctive therapy to uterine myomectomy or hysterectomy.


This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
A. Al-Hendy and S. Salama
Gene therapy and uterine leiomyoma: a review
Hum. Reprod. Update, July 1, 2006; 12(4): 385 - 400.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. R. Mason, R. A. Nowak, C. C. Morton, and J. J. Castellot Jr.
Heparin Inhibits the Motility and Proliferation of Human Myometrial and Leiomyoma Smooth Muscle Cells
Am. J. Pathol., June 1, 2003; 162(6): 1895 - 1904.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
E. Murase, E. S. Siegelman, E. K. Outwater, L. A. Perez-Jaffe, and R. W. Tureck
Uterine Leiomyomas: Histopathologic Features, MR Imaging Findings, Differential Diagnosis, and Treatment
RadioGraphics, September 1, 1999; 19(5): 1179 - 1197.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society